secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001193125-22-209391
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharmaceuticals appoints Roshawn Blunt as Class I director
----------------------------------------------------------------

- Roshawn Blunt appointed as Class I director effective August 2, 2022, term expiring at 2025 annual meeting.
- She will receive $40,000 annual cash retainer and an initial option grant of 35,000 shares vesting over three years.
- Further annual option grants of 17,500 shares, vesting by next annual meeting, with full acceleration on change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522209391/0001193125-22-209391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312522209391/d384999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-209391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer